Michael Katz1, Joseph Scherger2, Scott Conard3, Leslie Montejano4, Stella Chang5. 1. Clinical Associate Professor, Department of Pharmacy Practice and Science, College of Pharmacy, Tucson, AZ. 2. Clinical Professor of Family Medicine, Department of Family and Preventive Medicine, University of California-San Diego, CA. 3. Chief Medical Officer, MedicalEdge Healthcare Group, Dallas, TX. 4. Researcher at Thomson Reuters, Washington, DC. 5. Director at Thomson Reuters, Washington, DC.
Abstract
BACKGROUND: Controversy exists over the true therapeutic equivalence of branded and generic levothyroxine-the drug of choice for treating hypothyroidism-so professional societies recommend against switching between different formulations of the drug and suggest that patients who do switch be monitored. Payers typically encourage switching to generic drugs because of lower drug acquisition costs. OBJECTIVE: To evaluate the impact of switching levothyroxine formulations on actual healthcare costs. METHODS: Patients with hypothyroidism and at least 6 months of branded levothyroxine therapy were identified from a large healthcare claims database. Patients who subsequently switched to another levothyroxine formulation and could be followed for 6 months postswitch were matched to demographically similar patients who were continuous users of branded levothyroxine. Pre- and postswitch healthcare costs for each group were compared. RESULTS: The savings in prescription drug costs after switching from branded to generic levothyroxine are offset by increases in costs for other healthcare services, such that switching is actually associated with an increase, not a decrease, in total healthcare costs. CONCLUSION: In the absence of cost-savings, there is no clear rationale for switching patients from brand to generic levothyroxine.
BACKGROUND: Controversy exists over the true therapeutic equivalence of branded and generic levothyroxine-the drug of choice for treating hypothyroidism-so professional societies recommend against switching between different formulations of the drug and suggest that patients who do switch be monitored. Payers typically encourage switching to generic drugs because of lower drug acquisition costs. OBJECTIVE: To evaluate the impact of switching levothyroxine formulations on actual healthcare costs. METHODS:Patients with hypothyroidism and at least 6 months of branded levothyroxine therapy were identified from a large healthcare claims database. Patients who subsequently switched to another levothyroxine formulation and could be followed for 6 months postswitch were matched to demographically similar patients who were continuous users of branded levothyroxine. Pre- and postswitch healthcare costs for each group were compared. RESULTS: The savings in prescription drug costs after switching from branded to generic levothyroxine are offset by increases in costs for other healthcare services, such that switching is actually associated with an increase, not a decrease, in total healthcare costs. CONCLUSION: In the absence of cost-savings, there is no clear rationale for switching patients from brand to generic levothyroxine.
Authors: Jeffrey R Garber; James V Hennessey; Joseph A Liebermann; Charlene M Morris; Robert L Talbert Journal: J Fam Pract Date: 2006-06 Impact factor: 0.493
Authors: Joseph G Hollowell; Norman W Staehling; W Dana Flanders; W Harry Hannon; Elaine W Gunter; Carole A Spencer; Lewis E Braverman Journal: J Clin Endocrinol Metab Date: 2002-02 Impact factor: 5.958
Authors: P A Singer; D S Cooper; E G Levy; P W Ladenson; L E Braverman; G Daniels; F S Greenspan; I R McDougall; T F Nikolai Journal: JAMA Date: 1995-03-08 Impact factor: 56.272
Authors: Nan Huo; Li Chen; Ahmed Ullah Mishuk; Chao Li; Richard A Hansen; Ilene Harris; Zippora Kiptanui; Zhong Wang; Sarah K Dutcher; Jingjing Qian Journal: Endocrine Date: 2020-01-28 Impact factor: 3.633
Authors: Juan P Brito; Yihong Deng; Joseph S Ross; Nam Hee Choi; David J Graham; Yandong Qiang; Elena Rantou; Zhong Wang; Liang Zhao; Nilay D Shah; Kasia J Lipska Journal: Endocrine Date: 2022-02-02 Impact factor: 3.925